罗沙司他用于治疗慢性肾脏病相关贫血：为非透析、透析及移植后患者提供统一解决方案。 - Suppr

Suppr

超能文献

Roxadustat for CKD-related anemia: a unified solution for non-dialysis, dialysis, and post-transplant patients.

作者信息

Maaz Umair

机构信息

Rahbar Medical and Dental college, Lahore, Pakistan.

出版信息

Int Urol Nephrol. 2025 Jul;57(7):2337-2338. doi: 10.1007/s11255-025-04385-6. Epub 2025 Jan 25.

DOI:10.1007/s11255-025-04385-6

PMID:39862323

Abstract

摘要

相似文献

Roxadustat for CKD-related anemia: a unified solution for non-dialysis, dialysis, and post-transplant patients.罗沙司他用于治疗慢性肾脏病相关贫血：为非透析、透析及移植后患者提供统一解决方案。

Int Urol Nephrol. 2025 Jul;57(7):2337-2338. doi: 10.1007/s11255-025-04385-6. Epub 2025 Jan 25.

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.罗沙司他治疗非透析依赖性慢性肾脏病患者贫血的疗效和心血管安全性：三项随机临床试验的汇总结果。

Clin J Am Soc Nephrol. 2021 Aug;16(8):1190-1200. doi: 10.2215/CJN.16191020.

Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.罗沙司他（FG-4592）治疗透析依赖（DD）和非透析依赖（NDD）慢性肾脏病患者的贫血：系统评价和荟萃分析。

Pharmacol Res. 2020 May;155:104747. doi: 10.1016/j.phrs.2020.104747. Epub 2020 Mar 17.

Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan.透析依赖的 CKD 患者发生血栓栓塞事件的风险因素：日本罗沙司他 3 期试验的汇总分析。

Adv Ther. 2024 Apr;41(4):1526-1552. doi: 10.1007/s12325-023-02727-3. Epub 2024 Feb 16.

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease.罗沙司他对非透析慢性肾脏病患者贫血、铁代谢及脂质代谢的影响。

Front Med (Lausanne). 2023 Feb 22;10:1071342. doi: 10.3389/fmed.2023.1071342. eCollection 2023.

Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.罗沙司他治疗未透析慢性肾脏病患者贫血的随机 3 期研究结果。

J Am Soc Nephrol. 2021 Mar;32(3):737-755. doi: 10.1681/ASN.2020081150. Epub 2021 Feb 10.

A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.一项评估罗沙司他间歇口服给药治疗未接受透析的非透析慢性肾脏病且对红细胞生成刺激剂初治的日本贫血患者的 3 期、多中心、随机、双盲、开放性研究

Nephron. 2020;144(8):372-382. doi: 10.1159/000508100. Epub 2020 Jun 24.

Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.罗沙司他治疗非透析和透析依赖性慢性肾脏病贫血患者的铁状态变化。

Kidney360. 2022 Jun 29;3(9):1511-1528. doi: 10.34067/KID.0001442022. eCollection 2022 Sep 29.

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.罗沙司他与红细胞生成刺激剂治疗非透析依赖或透析相关慢性肾脏病贫血患者的安全性：四项 3 期研究的汇总分析。

Adv Ther. 2023 Apr;40(4):1546-1559. doi: 10.1007/s12325-023-02433-0. Epub 2023 Feb 7.

Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.罗沙司他治疗慢性肾脏病患者贫血的安全性和有效性：一项荟萃分析和试验序贯分析

Front Med (Lausanne). 2021 Aug 31;8:724456. doi: 10.3389/fmed.2021.724456. eCollection 2021.

本文引用的文献

Clinical effect of roxadustat vs. erythropoietin in non-dialysis CKD with diabetes: a single center propensity score matching analysis.罗沙司他对比促红细胞生成素治疗非透析慢性肾脏病合并糖尿病的临床效果：一项单中心倾向评分匹配分析。

Int Urol Nephrol. 2024 Aug;56(8):2683-2693. doi: 10.1007/s11255-024-03983-0. Epub 2024 Mar 15.

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review.罗沙司他用于移植后贫血患者：一项叙述性综述。

Kidney Dis (Basel). 2023 Nov 10;10(1):32-38. doi: 10.1159/000535071. eCollection 2024 Feb.

Anaemia in CKD-treatment standard.慢性肾脏病治疗标准中的贫血

Nephrol Dial Transplant. 2024 Apr 26;39(5):770-777. doi: 10.1093/ndt/gfad250.

A clinical study on roxadustat for anemia in diabetic nephropathy: a 8-week study.罗沙司他治疗糖尿病肾病贫血的临床研究：一项为期8周的研究。

Int Urol Nephrol. 2024 Mar;56(3):1093-1101. doi: 10.1007/s11255-023-03757-0. Epub 2023 Aug 25.

Prevalence of anemia and its predictors among patients with chronic kidney disease admitted to a teaching hospital in Ethiopia: A hospital-based cross-sectional study.在埃塞俄比亚一所教学医院住院的慢性肾脏病患者中贫血的患病率及其预测因素：一项基于医院的横断面研究。

Medicine (Baltimore). 2023 Feb 10;102(6):e31797. doi: 10.1097/MD.0000000000031797.

Adv Ther. 2023 Apr;40(4):1546-1559. doi: 10.1007/s12325-023-02433-0. Epub 2023 Feb 7.

Roxadustat: Do we know all the answers?罗沙司他：我们是否已经了解所有的答案？

Biomol Biomed. 2023 May 1;23(3):354-363. doi: 10.17305/bb.2022.8437.

Hypoxia inducible factor-prolyl hydroxylase inhibitors in anemic patients with non-dialysis dependent chronic kidney disease: a meta-analysis of randomized clinical trials.缺氧诱导因子脯氨酰羟化酶抑制剂在非透析依赖性慢性肾脏病伴贫血患者中的应用：一项随机临床试验的荟萃分析。

Int Urol Nephrol. 2023 Jan;55(1):167-171. doi: 10.1007/s11255-022-03300-7. Epub 2022 Jul 19.

HIF-PHIs for Anemia Management in CKD: Potential and Uncertainty ASCEND.用于慢性肾脏病贫血管理的低氧诱导因子脯氨酰羟化酶抑制剂：潜力与不确定性——ASCEND研究

Clin J Am Soc Nephrol. 2022 Aug;17(8):1255-1258. doi: 10.2215/CJN.02440222. Epub 2022 Jul 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验